

Note: This document has been translated from a part of the Japanese original for reference purposes only.  
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Securities code: 4554

December 1, 2025

(Commencement of measures for providing information in electronic format: November 27, 2025)

**To our shareholders:**

Shuhei Morita  
President & CEO  
**Fuji Pharma Co., Ltd.**  
5-7 Sanban-cho, Chiyoda-ku, Tokyo

## **Notice of the 61th Ordinary General Meeting of Shareholders**

You are hereby notified that the 61th Ordinary General Meeting of Shareholders of Fuji Pharma Co., Ltd. (the “Company”) will be held as indicated below.

For the meeting, the Company takes measures to provide materials for the meeting in electronic format and posts them under the headline “Notice of the 61th Ordinary General Meeting of Shareholders” on the website below:

- The Company’s Website:
  - <https://www.fujipharma.jp/english/ir/>

In addition to the website above, they are also available on the website below:

- Tokyo Stock Exchange Website (TSE Listed Company Search):
  - <https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do?Show=Show>

To access the materials at the TSE website, please enter the Company’s name “Fuji Pharma” or securities code “4554”, click on [Basic Information] and select the [Documents for public inspection/PR information].

You are kindly requested to exercise your voting rights in writing or via the Internet in advance.

If there is any change regarding the holding of the General Meeting of Shareholders due to future changes, we will post a notice on the Company website (<https://www.fujipharma.jp/english/ir/>).

- 1. Date and time:** Friday, December 19, 2025, 10:00 a.m. (JST)  
(Reception will open at 9:00 a.m.)
- 2. Venue:** **Grand Hall, 8th Floor of TKP ICHIGAYA CONFERENCE CENTER**  
8 Ichigaya-Hachimancho, Shinjuku-ku, Tokyo
- 3. Purpose of the Meeting**  
**Matters to be reported:**
  1. The Business Report and the Consolidated Financial Statements for the 61th fiscal year (from October 1, 2024 to September 30, 2025), and the results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Audit & Supervisory Board
  2. The Non-consolidated Financial Statements for the 61th fiscal year (from October 1, 2024 to September 30, 2025)

**Matters to be resolved:**

Proposal No. 1	Appropriation of Surplus
Proposal No. 2	Election of Nine Directors
Proposal No. 3	Revision of the Amount of Remuneration for Directors
Proposal No. 4	Revision of the Amount of Remuneration for Audit & Supervisory Board Members

- If you are attending the meeting, please submit the enclosed voting rights exercise form to the reception desk.
- In accordance with laws, regulations and Article 15 of the Company's Articles of Incorporation, the documents below are not included in the documents sent to shareholders who have requested paper-based documents. The documents sent to those shareholders are, therefore, part of the documents that the Audit & Supervisory Board Members and the Accounting Auditors audited when they prepared their respective audit reports.
  - The System to Ensure Proper Business Operations and the Operational Status of the System as well as Basic Policy Regarding Control of the Company of the Business Report
  - The Consolidated Statement of Changes in Equity and Notes to the Consolidated Financial Statements of the Consolidated Financial Statements
  - Statement of Changes in Equity and Notes to the Financial Statements of the Non-consolidated Financial Statements
- If any revisions are made to the documents available digitally, revised documents will be posted on the corresponding website of the Company.

## **Reference Documents for the General Meeting of Shareholders**

### **Proposal No. 1 Appropriation of Surplus**

The Company's basic policy is to continue to provide stable dividends to shareholders, and taking into consideration the business performance of the fiscal year and future business development, as well as the internal reserves necessary to strengthen the Company's financial structure, the Company proposes to pay a year-end dividend of ¥25.5 per share for the 61th fiscal year.

#### **1. Type of dividend property**

To be paid in cash.

#### **2. Allotment of dividend property to shareholders and the total amount**

The Company proposes to pay a dividend of ¥25.5 per common share of the Company. In this event, the total dividends will be ¥624,634,154.

#### **3. Effective date of dividends of surplus**

The effective date of dividends will be December 22, 2025.

## Proposal No. 2 Election of Nine Directors

The terms of office of all eight Directors will expire at the conclusion of this meeting. In that regard, the Company proposes the election of nine Directors.

The candidates for Director are as follows:

Candidate No.	Name	Current Position in the Company	Candidate Attributes
1	Takayuki Iwai	Chairman & Representative Director	Reelection
2	Shuhei Morita	President & CEO	Reelection
3	Toyoyuki Kamide	Director and Vice President	Reelection
4	Satoshi Suzuki	Director and Vice President	Reelection
5	Keiji Hirai	Director	Reelection Outside Independent
6	Keiko Kiyama	Director	Reelection Outside Independent
7	Minoru Ozawa	Director	Reelection Outside
8	Kiyohisa Hirano	Director	New election Outside Independent
9	Reiko Kojima	Director	New election Outside Independent

Reelection Candidate for Director to be reelected

New election Candidate for Director to be newly elected

Outside Candidate for outside Director

Independent Independent officer

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of shares of the Company owned
1	<div>Reelection</div> <b>Takayuki Iwai</b> (February 24, 1964)	Apr. 1986    Joined MITSUI & CO., LTD. Jun. 1991    Mitsui & Co. Italia S.p.A. Jun. 1995    Office of Pharmaceutical and Medical Businesses, Life Science Business Department, MITSUI & CO., LTD. Feb. 2003    General Manager, Specialty Chemical Products Department, Mitsui & Co. Deutschland GmbH Dec. 2006    Seconded to the Company Director and Group Manager, Corporate Planning Office Jul. 2008    Office of European Businesses, Agricultural Science Business Department, MITSUI & CO., LTD. Jul. 2011    General Manager, Medical and Healthcare Business Div. II, Consumer Services Business Unit Jul. 2017    General Manager, the Americans Business Unit, the Consumer Service Business Goods Division, Mitsui & Co. (USA), Inc. Oct. 2019    Joined the Company Vice President & COO, General Manager of Research & Development Division Oct. 2019    President, General Manager of Research & Development Division Dec. 2019    President & CEO, General Manager of Research & Development Division Jan. 2021    Director, OLIC (Thailand) Limited Oct. 2024    Chairman & Representative Director (current position)	14,954

#### Reasons for nomination as a candidate for Director

Takayuki Iwai has acquired abundant knowledge and experience in the field of pharmaceuticals by working as an executive at a major trading firm for many years. He has been serving as President & CEO of the Company since December 2019 and as Chairman & Representative Director since October 2024. Considering that he can contribute to the medium- to long-term enhancement of corporate value by leveraging his abundant knowledge, experience and abilities, the Company has renominated him as a candidate for Director.

2	<div>Reelection</div> <b>Shuhe Morita</b> (December 11, 1974)	Apr. 1998    Joined Fujisawa-Fisons Co., Ltd. (Currently Sanofi K.K.) Jun. 2003    Joined GlaxoSmithKline plc. Jul. 2009    Joined Meiyu Industry Co., Ltd. Sep. 2010    Joined the Company Oct. 2016    Corporate Officer Senior Manager of Sales Department Oct. 2018    General Manager of Sales Division Oct. 2019    General Manager of Sales Division and General Manager of Strategic Marketing Planning Department Oct. 2021    Executive Corporate Officer General Manager, Supply Chain Management Department Oct. 2023    General Manager, Corporate Planning Department Oct. 2024    President & CEO (current position) Jan. 2025    Director, OLIC (Thailand) Limited (current position)	4,241
---	--	---	-------

#### Reasons for nomination as a candidate for Director

Having abundant experience in sales and marketing at pharmaceutical companies, Shuhe Morita served as manager of sales sections and supply chain management at the company. He has been serving as Director of the Company since December 2023 and as President & CEO of the Company since October 2024. Considering that he can contribute to the medium- to long-term enhancement of corporate value by leveraging his abundant knowledge, experience and abilities, the Company has renominated him as a candidate for Director.

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of shares of the Company owned
3	<b>Toyoyuki Kamide</b> (March 1, 1965)  <b>Reelection</b>	Apr. 1987      Joined Nomura Trading Co., Ltd. Apr. 2000      Joined the Company Oct. 2000      Group Manager, Corporate Planning Office Dec. 2003      Director Oct. 2006      Group Manager, Administration Department Oct. 2010      Senior Manager, Administration Department Oct. 2012      Director, OLIC (Thailand) Limited Oct. 2013      Seconded to OLIC (Thailand) Limited, Managing Director Mar. 2015      Corporate Officer, the Company Oct. 2016      Executive Corporate Officer Oct. 2017      General Manager of Corporate Headquarters Division, General Manager of Corporate Planning Department Dec. 2017      Director (current position) Oct. 2019      General Manager, Corporate Business Management Department Oct. 2020      General Manager, Supply Chain Management Department Oct. 2021      Vice President, Plant Manager of the Toyama Plant (current position) Nov. 2021      Director, OLIC (Thailand) Limited (current position) Nov. 2021      Vice President, Head of Corporate Management Division (current position)	21,373

#### Reasons for nomination as a candidate for Director

Toyoyuki Kamide served as manager of corporate sections and a plant of the Company and Managing Director of an overseas subsidiary. Considering that he can contribute to the medium- to long-term enhancement of corporate value by leveraging his abundant knowledge, experience and abilities, the Company has renominated him as a candidate for Director.

4	<b>Satoshi Suzuki</b> (July 26, 1963)  <b>Reelection</b>	Apr. 1989      Joined Eisai Co., Ltd. Apr. 2002      Director of Europe, Eisai Ltd. (currently Eisai Europe Ltd.) Jun. 2004      President, General Manager, Eisai S.A.S Jun. 2010      Head of Strategic Planning, Asia Division, Eisai China Inc. Apr. 2011      Vice President President, Eisai (Suzhou) Trading Co., Ltd. Oct. 2012      Head of Global Planning Department, Eisai Co., Ltd. Dec. 2012      Head of Management, Human Development Division, Talent Management Department Jul. 2013      Joined Irom Pharmaceuticals Co., Ltd. (currently neo CitiCare Pharma Co., Ltd.) Jan. 2014      President and Representative Director Apr. 2014      Representative Director, YL Biologics Limited Mar. 2016      Joined Santen Pharmaceutical Co., Ltd. Corporate Officer, Head of Asia Division Apr. 2017      Corporate Officer, Head of Corporate Development Division Oct. 2017      Senior Corporate Officer, Head of Corporate Development Division Aug. 2022      Joined the Company Vice President, General Manager of Corporate Strategy Division (current position) Dec. 2022      Director (current position) Jan. 2025      Director, OLIC (Thailand) Limited (current position)	1,304
---	---	--	-------

#### Reasons for nomination as a candidate for Director

Satoshi Suzuki has acquired abundant knowledge and experience in the field of pharmaceuticals by working as an executive at major pharmaceutical companies for many years. He has been serving as Director of the Company since December 2022.

Considering that he can contribute to the medium- to long-term enhancement of corporate value by leveraging his abundant knowledge, experience and abilities, the Company has renominated him as a candidate for Director.

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of shares of the Company owned
5	<div>Reelection</div> <div>Outside</div> <div>Independent</div> <b>Keiji Hirai</b> (October 31, 1949)	Apr. 1972      Joined KYORIN Pharmaceutical Co., Ltd. Jun. 2002      Director, General Manager of Drug Discovery Research Headquarters Department Dec. 2004      Director, ActivX Biosciences, Inc. (SanDiego) Jun. 2005      Director, Managing Executive Officer, General Manager of Drug Discovery Research Headquarters Department, KYORIN Pharmaceutical Co., Ltd. Jan. 2006      Director in charge of Intellectual Property, KYORIN Co., Ltd. Jun. 2007      Director, Senior Executive Officer in charge of Intellectual Property Director, Senior Executive Officer, General Manager of Research Headquarters, in charge of Intellectual Property, KYORIN Pharmaceutical Co., Ltd. Jun. 2008      Director, Senior Executive Officer in charge of Research and Development and Intellectual Property, KYORIN Co., Ltd. Director, Senior Executive Officer, General Manager of Research Headquarters, in charge of Development Headquarters and Intellectual Property, KYORIN Pharmaceutical Co., Ltd. Jun. 2009      Director, KYORIN Co., Ltd. Representative Director, President and Chief Executive Officer, General Manager of Research and Development Headquarters, in charge of Business Development, KYORIN Pharmaceutical Co., Ltd. Jun. 2012      Director, Corporate Advisor, KYORIN Pharmaceutical Co., Ltd. Jun. 2013      Corporate Advisor Dec. 2016      Outside Director, the Company (current position) Jan. 2018      Outside Director, Trans Chromosomics, Inc. Jun. 2018      Program Officer of Research Program on Emerging and Re-emerging Infectious Diseases, Japan Agency for Medical Research and Development (AMED) (current position) May 2019      Evaluation Committee Member, Japan Agency for Medical Research and Development (AMED) Nov. 2022      Visting Professor, Omura Satoshi Memorial Institute, The Kitasato Institute, Kitasato University (current position) Jun. 2023      Visiting Professor, Organization for the Promotion of Research and Social Collaboration, University of Yamanashi, Organization for the Promotion of Research and Social Collaboration (current position) Jun. 2024      Chief advisor, Omura Memorial Research Flotilla for Microbial Resources (current position)	6,900

**Reasons for nomination as a candidate for outside Director and expected role**

Keiji Hirai has experience as a corporate manager of a pharmaceutical company and abundant knowledge he acquired through research and development. Expecting him to contribute to the medium- to long-term enhancement of corporate value in areas such as pharmaceutical research and development and sales planning, the Company has nominated him as a candidate for outside Director.

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of shares of the Company owned
6	<div> <div>Reelection</div> <div>Outside</div> <div>Independent</div> </div> <b>Keiko Kiyama</b> (February 21, 1960)	Apr. 1982    Joined Trade Department of Sankosha Corporation May 1986    Joined Kosan Trading Co., Ltd. May 1992    Joined Uniscope Corporation (currently Uniscope Research and Development Corporation) May 1993    Joined GLOBAL LINK MANAGEMENT INC. May 1994    Co-founded Japan Emergency NGO (JEN) Regional Representative of the former Yugoslavia business Apr. 2000    Trustee Jul. 2000    Trustee and Secretary General Apr. 2007    Trustee, AKARUI SHAKAIDUKURIUNDU Jun. 2007    Trustee, Japan NGO Center for International Cooperation Apr. 2011    Co-Chairperson and Executive Director, Japan Platform Feb. 2014    Board of Councilor, Global Fund for Education Assistance Apr. 2016    President of the board of Trustees, Japan Emergency NGO (JEN) Apr. 2016    Councilor, NHK International Broadcast Council May 2016    Director, Rikkyo Educational Corporation Sept. 2016    Advisory member, the United Nations Central Emergency Response Fund Sept. 2018    Trustee and Secretary General, Trustees Japan Emergency NGO (JEN) (current position) Jun. 2020    Trustee, Global Fund for Education Assistance Dec. 2020    Outside Director, the Company (current position) Jun. 2025    Auditor, Institute for the Fusion of Eastern and Western Knowledge (current position)	2,100
<b>Reasons for nomination as a candidate for Director and expected role</b> Keiko Kiyama has global experience in international support activities, long experience of organizational management and high level of insight on diversity management. Expecting her to contribute to the medium- to long-term enhancement of corporate value, the Company has nominated her as a candidate for outside Director.			



Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of shares of the Company owned
7	<div>Re election</div> <div>Outside</div> <b>Minoru Ozawa</b> (January 23, 1962)	Apr. 1984    Joined The Taiyo Kobe Bank Limited (currently Sumitomo Mitsui Banking Corporation) Aug. 1994    Chief Dealer of Spot USD/JPY Desk (in charge of Bank of Japan), Foreign Exchange and International Treasury Division (Tokyo), The Sakura Bank, Limited (currently Sumitomo Mitsui Banking Corporation) Jan. 1995    Member of Tokyo Foreign Exchange Market Practices Committee (currently Tokyo Foreign Exchange Market Committee) Jul. 1997    Head of Option Desk (Joint Head of Trading Group), Foreign Exchange and International Treasury Division (London), The Sakura Bank, Limited (currently Sumitomo Mitsui Banking Corporation) Oct. 1997    Head of Trading Group, Global Markets Trading Division (London), Investment Banking DC Apr. 2001    Head of Trading Group, Global Markets Trading Department (London), Sumitomo Mitsui Banking Corporation Jul. 2003    Senior Manager, Financial Consulting Department Oct. 2003    Senior Manager, Private Banking Department Jan. 2004    Private Banker, Deputy General Manager, Private Banking Department Jul. 2005    Established Certified Administrative Procedures Legal Specialist Ozawa Legal Office Principal (current position) Nov. 2007    Joined UBS Wealth Management (UBS AG, Tokyo Branch) Director, Desk Head Sept. 2010    Joined FJ Planning Ltd. (currently FJP Ltd.) President and Chief Executive Officer (current position) Jan. 2011    Established Value Create Partners Corporation President and Chief Executive Officer (current position) Apr. 2012    Regular Member, General Incorporated Association Cosmos Institute of General Adult Guardianship Support Center (currently Public Interest Incorporated Association Cosmos Institute of General Adult Guardianship Support Center) (current position) Oct. 2017    Executive Partner, Takuwa (Japan) Corporation Dec. 2019    Joined The Seiichi Imai Memorial Foundation Managing Director and Secretary General (current position) Mar. 2020    Joined Image Plan Co., Ltd. President and CEO (current position)	2,800

**Reasons for nomination as a candidate for Director and expected role**

Minoru Ozawa has acquired abundant experience by working as an executive at financial institutions for many years, broad insight as a corporate manager, and financial expertise that also considers an investor's perspective. Expecting him to contribute to the medium- to long-term enhancement of corporate value, the Company has nominated him as a candidate for outside Director.

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of shares of the Company owned
8	<div> <div>New election</div> <div>Outside</div> <div>Independent</div> </div> <b>Kiyohisa Hirano</b> (May 12, 1963)	Apr. 1986      Joined Daiwa Securities Co., Ltd. Apr. 2010      President and CEO, Daiwa Quantum Capital Limited Apr. 2013      Director, Daiwa PI Partners Co., Ltd. Apr. 2014      Director, Daiwa Corporate Investment Co., Ltd. Apr. 2020      President and CEO Oct. 2024      Advisor, Link Partners Law Firm (current position)	0

**Reasons for nomination as a candidate for outside Director and expected role**

Kiyohisa Hirano has abundant experience in the securities and investment sector gained over many years, a high level of insight into the capital market, and practical experience that also considers an investor's perspective. Expecting him to contribute to the medium- to long-term enhancement of corporate value, the Company has nominated him as a candidate for outside Director.

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company, and significant concurrent positions outside the Company	Number of shares of the Company owned
9	<div> <div>New election</div> <div>Outside</div> <div>Independent</div> </div> <b>Reiko Kojima</b> (September 26, 1975)	Mar. 2002      Acquisition of physician's license, position in general hospital May 2002      Regular outpatient physician, department of psychosomatic medicine at general hospital, Company Physician, Furukawa Electric Co., Ltd. Mar. 2010      Doctor of Medicine Apr. 2011      Company Physician, MARUI GROUP CO., LTD. (current position) Apr. 2014      General Manager, Health Management Division Apr. 2019      Executive Officer Apr. 2020      Executive Officer, General Manager, Wellbeing Promotion Department May 2021      Executive Officer, General Manager and CWO (Chief Well-being Officer), Wellbeing Promotion Department Jun. 2021      Director, Executive Officer, and CWO, General Manager, Wellbeing Promotion Department Apr. 2023      Director, Senior Executive Officer, and CWO, General Manager, Wellbeing Promotion Department (current position)	0

**Reasons for nomination as a candidate for outside Director and expected role**

Reiko Kojima has a high level of insight into human capital management at companies in addition to her expertise as a physician, Doctor of Medicine, and occupational physician. Expecting her to contribute to the medium- to long-term enhancement of corporate value, the Company has nominated her as a candidate for outside Director.

(Notes)

1. Minoru Ozawa serves as President and CEO of FJP Ltd., which owns 17.58% of the Company's shares as of September 30, 2025.
2. There is no special interest between any of the candidates and the Company.
3. Keiji Hirai, Keiko Kiyama, Minoru Ozawa, Kiyohisa Hirano and Reiko Kojima are candidates for Outside Director stipulated in Article 2, paragraph (3), item (7) of the Ordinance for Enforcement of the Companies Act.
4. The Company has submitted notification to the Tokyo Stock Exchange that Keiji Hirai and Keiko Kiyama have been designated as independent officers as provided for by the aforementioned exchange. If they are reelected as proposed and if Kiyohisa Hirano and Reiko Kojima are elected as proposed, the Company will designate them as independent officers.
5. As Outside Director, Keiji Hirai will have served for nine years, and Keiko Kiyama will have served for five years at the conclusion of the meeting.
6. The Company has entered into limited liability agreements with Keiji Hirai, Keiko Kiyama and Minoru Ozawa to limit their liability to the amount stipulated in Article 425, paragraph (1) of the Companies Act, and will continue the agreements if Keiji Hirai, Keiko Kiyama and Minoru Ozawa are reelected as proposed.
7. If the election of Kiyohisa Hirano and Reiko Kojima is approved, the Company plans to enter into limited liability agreements with them to limit their liability to the amount stipulated in Article 425, paragraph (1) of the Companies Act.
8. The Company has concluded a directors and officers liability insurance policy with an insurance company as stipulated in Article 430-3, paragraph (1) of the Companies Act, and an overview of the insurance policy is stated on page 29 in the Business Report (Written in Japanese only). If the election of the candidates for Director is approved, they will be included as the insureds under this policy. In addition, when the insurance policy is renewed, the Company plans to renew the policy with the same terms.

(Reference) Expertise and Experience of Candidates for Director (Skill Matrix)

The expertise and experience of the candidates for Director are as follows.

	Name	Management	Global	Research and Development	Finance	Legal Risk Management	Sales and Marketing	Sustainability	IT DX	Human Resources, Development
Directors	Takayuki Iwai	●	●	●		●		●		
	Shuhei Morita	●					●	●	●	●
	Toyoyuki Kamide	●	●		●	●		●	●	●
	Satoshi Suzuki	●	●	●	●		●	●		●
	Keiji Hirai	●	●	●				●		
	Keiko Kiyama	●	●							●
	Minoru Ozawa	●	●		●			●		●
	Kiyohisa Hirano	●			●					
	Reiko Kojima	●						●		●

### **Proposal No. 3    Revision of the Amount of Remuneration for Directors**

The amount of remuneration for the Company's Directors was approved at the 50th Ordinary General Meeting of Shareholders held on December 19, 2014, and the Extraordinary General Meeting of Shareholders held on July 22, 2019, to be "up to ¥200 million per year (including up to ¥30 million for outside Directors, excluding the salary portion for Directors who are also employees)" and has remained unchanged to date. In recent years, the roles and responsibilities required of directors have significantly increased. While primarily benchmarking against Japanese companies in the same industry or of similar scale, the Company proposes the revision of the amount of remuneration for Directors to "up to ¥400 million per year (including up to ¥50 million for outside Directors, excluding the salary portion for Directors who are also employees)" to ensure a level of remuneration appropriate for securing and retaining diverse and excellent talent with the aim of further growth.

Before submission, this proposal has been reviewed by the Nomination and Remuneration Committee whose chairperson and a majority of members are independent outside Directors and the Company believes that the content of this proposal is appropriate.

If Proposal No. 2 is approved as proposed, the number of Directors subject to this proposal will be nine (including five outside Directors).

**Proposal No. 4    Revision of the Amount of Remuneration for Audit & Supervisory Board Members**

The amount of remuneration for the Company's Audit & Supervisory Board Members was approved at the 29th Ordinary General Meeting of Shareholders held on December 24, 1993 to be "up to \30 million per year" and has remained unchanged to date. Many years have passed since the last revision of the amount of remuneration, and considering the changes in economic conditions during this period, the diversification of duties undertaken by Audit & Supervisory Board Members, and the resulting increase in responsibilities, the Company proposes the revision of the amount of remuneration for Audit & Supervisory Board Members to "up to \40 million per year" to ensure a level of remuneration effective for securing and retaining excellent talent.

The Company currently has three Audit & Supervisory Board Members (including two outside Audit & Supervisory Board Members) and the number of Audit & Supervisory Board Members subject to this proposal will be unchanged (the number of outside Audit & Supervisory Board Members will also be unchanged).